EUVIMEDEUVIMED entdecken
Crossref

Estimating Anticancer Effects of Yohimbine in DMBA‐Induced Oral Carcinogenesis Hamster Model: Utilizing Biochemical and Immunohistochemical Techniques

Nasimudeen R Jabir iD, Shams Tabrez, Nojood Altwaijry, Mohd Shahnawaz Khan iD, Arun Kumar Ramu, Bakrudeen Ali Ahmed

Cell Biochemistry and Function · 2024

DOI: 10.1002/cbf.4132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biochemistry and Function, 2024. Verfasst von Nasimudeen R Jabir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biotechnology, Centre for Research and Development, PRIST University, Thanjavur, Tamil Nadu, India. Hauptthemen laut MEDLINE: Mouth Neoplasms, Yohimbine, 9,10-Dimethyl-1,2-benzanthracene. Die Arbeit nennt 70 Literaturangaben. Gefördert von: This study was supported by Deanship of Scientific Research (DSR), King Abdulaziz University, Grant/Award Number: GPIP: 86-141-2024., King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yohimbine is a potent bioactive indole alkaloid, isolated from a variety of biological sources and has long been used as a natural stimulant and aphrodisiac, particularly to treat erectile dysfunction. However, some literature also points toward its anticancer effect in different experimental models. The current study aimed to address a clinical concern on the therapeutic utilization of yohimbine as a repurposed drug. We employed 7,12‐dimethylbenz[a]anthracene (DMBA)‐induced hamster buccal pouch carcinogenesis model juxtaposed with biochemical investigation of several detoxification and antioxidant markers, such as Cyt p450, Cyt b5, thiobarbituric acid reactive substance (TBARS), glutathione (GSH), glutathione reductase (GR), glutathione S transferase (GST), DT‐diaphorase, vitamin C, vitamin E, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). The immunohistochemical assessment of cyclooxygenase‐2 (COX‐2), interleukin‐6 (IL‐6), proliferating cell nuclear antigen (PCNA), and cyclin D1 expression were also performed to observe the effect of yohimbine on these markers. The hamsters treated with DMBA presented the growth of tumors in the buccal pouches, accompanied by significant changes in the liver and buccal mucosa levels of Phase I & II detoxification enzymes and lipid peroxidation (LPO). A significant rise in the range of 2‐ to 3.5‐fold was observed in Cyt p450, Cyt b5, and LPO in DMBA‐treated animals. However, oral administration of yohimbine significantly restored the LPO, antioxidant, and detoxifying enzyme activities. Additionally, the levels of COX‐2, IL‐6, PCNA, and cyclin D1 were also found to be downregulated by yohimbine treatment. In conclusion, yohimbine improved the biochemical and immunohistochemical markers of DMBA‐induced oral cancer and reverted to near normal values via ameliorating the underlying inflammation and oxidative stress conditions. Our study highlighted the potential of yohimbine as anticancer agent, especially against oral cancer and suggested its possible use as repurposed drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsYohimbine9,10-Dimethyl-1,2-benzanthraceneAnimalsCricetinaeMaleDisease Models, AnimalImmunohistochemistryAntineoplastic AgentsMesocricetusAntioxidantsProliferating Cell Nuclear AntigenCarcinogenesis

Stichwörter der Autor:innen

anticancerdetoxificationdrug‐repurposingoral carcinogenesisyohimbine

Substanzen

Yohimbine9,10-Dimethyl-1,2-benzanthraceneAntineoplastic AgentsAntioxidantsProliferating Cell Nuclear Antigen

Autor:innen und Institutionen

  • Department of Biochemistry and Biotechnology, Centre for Research and Development, PRIST University, Thanjavur, Tamil Nadu, India.
  • King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Protein Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Nasimudeen R Jabir, Mohd Shahnawaz Khan

Förderung

  • This study was supported by Deanship of Scientific Research (DSR), King Abdulaziz University, Grant/Award Number: GPIP: 86-141-2024.
  • King Abdulaziz University

Zitieren

APA

Jabir, N. R., Tabrez, S., Altwaijry, N., Khan, M. S., Ramu, A. K., & Ahmed, B. A. (2024). Estimating Anticancer Effects of Yohimbine in DMBA‐Induced Oral Carcinogenesis Hamster Model: Utilizing Biochemical and Immunohistochemical Techniques. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.4132

Vancouver

Jabir NR, Tabrez S, Altwaijry N, Khan MS, Ramu AK, Ahmed BA. Estimating Anticancer Effects of Yohimbine in DMBA‐Induced Oral Carcinogenesis Hamster Model: Utilizing Biochemical and Immunohistochemical Techniques. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.4132

BibTeX
@article{Jabir2024,
  author = {Jabir, Nasimudeen R and Tabrez, Shams and Altwaijry, Nojood and Khan, Mohd Shahnawaz and Ramu, Arun Kumar and Ahmed, Bakrudeen Ali},
  title = {Estimating Anticancer Effects of Yohimbine in DMBA‐Induced Oral Carcinogenesis Hamster Model: Utilizing Biochemical and Immunohistochemical Techniques},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  doi = {10.1002/cbf.4132}
}
Kostenlos starten →